Global Third-Generation Sequencing Market Size By Type (Single Molecule Real Time (SMRT) DNA Sequencing, Nanopore-based Single-Molecule Analysis Technology), By Application (Oncology, Hereditary Disea...

The Global Third-Generation Sequencing Market was valued at USD 8.3 billion in 2023 and is projected to reach USD 18.9 billion by 2031, growing at a CAGR of 10.8% during the forecast period (2023-2031). The market growth is fueled by the rising adoption of long-read sequencing technologies, increasing demand for personalized medicine, and advancements in genomics research.

Third-generation sequencing (TGS) represents a revolutionary approach to DNA sequencing, offering real-time, single-molecule analysis capabilities. Unlike first- and second-generation sequencing technologies, TGS provides longer read lengths, higher accuracy, and faster turnaround times. The expanding application of TGS in oncology, infectious disease diagnostics, and agricultural genomics is further driving its market growth.

Drivers

Growing Demand for Personalized Medicine

The increasing focus on precision medicine and personalized therapies is a major driver of the TGS market. The ability of third-generation sequencing to provide highly accurate genetic insights helps in tailoring treatments to individual patients, particularly in oncology and rare disease diagnosis.

Technological Advancements in Long-Read Sequencing

Ongoing innovations in sequencing platforms, such as Nanopore Sequencing and Single-Molecule Real-Time (SMRT) sequencing, are improving read accuracy and reducing sequencing costs. These advancements are enhancing the adoption of TGS in research and clinical settings.

Rising Investments in Genomics Research

Governments and private organizations are heavily investing in genomics research, fueling the expansion of third-generation sequencing technologies. Various national genome projects and initiatives aimed at understanding complex diseases are boosting market growth.

Restraints

High Cost of Third-Generation Sequencing Systems

Despite technological advancements, the high initial cost of sequencing platforms and operational expenses remain significant barriers to adoption, particularly for small research laboratories and healthcare facilities in developing regions.

Data Analysis and Interpretation Challenges

The complex nature of TGS data requires advanced bioinformatics tools and expertise for interpretation. The lack of standardized computational solutions and skilled professionals in genomic data analysis poses challenges for widespread adoption.

Opportunities

Expansion of TGS in Infectious Disease Diagnostics

The COVID-19 pandemic highlighted the importance of rapid and accurate pathogen sequencing. TGS is increasingly being used for real-time viral genome sequencing, aiding in outbreak monitoring and epidemiological studies. The technology’s potential to revolutionize infectious disease diagnostics presents a significant market opportunity.

Integration with AI and Cloud Computing

The integration of artificial intelligence (AI) and cloud-based platforms with TGS data analysis is enhancing efficiency and scalability. AI-driven algorithms are improving the accuracy of variant detection and disease prediction, making genomic insights more accessible.

Market by System Type Insights

Nanopore Sequencing Dominates the Market

Among the system types, Nanopore Sequencing Technology accounted for the largest market share in 2023. Its real-time sequencing capability and portability make it a preferred choice for clinical and field applications. Additionally, Single-Molecule Real-Time (SMRT) sequencing is gaining traction due to its high accuracy in detecting structural variants and epigenetic modifications.

Market by End-Use Insights

Hospitals & Clinics Leading the Adoption

The hospitals and clinics segment held the largest revenue share in 2023, driven by the increasing use of TGS for disease diagnosis, treatment selection, and monitoring. Research institutions and pharmaceutical companies are also significantly contributing to market growth through genomic research and drug development initiatives.

Market by Regional Insights

North America Holds the Largest Share

North America dominated the Global Third-Generation Sequencing Market in 2023, accounting for over 40% of the global revenue. The region’s strong research infrastructure, high healthcare spending, and presence of leading genomics companies are key factors driving market growth.

Asia-Pacific Expected to Witness the Fastest Growth

The Asia-Pacific region is projected to experience the highest CAGR during the forecast period. Increasing investments in genomics research, a growing focus on personalized medicine, and government initiatives supporting biotechnology are fueling market expansion in countries like China, Japan, and India.

Competitive Scenario

Key players in the Global Third-Generation Sequencing Market include:

Pacific Biosciences of California, Inc.

Oxford Nanopore Technologies

Illumina, Inc.

QIAGEN N.V.

BGI Genomics

Thermo Fisher Scientific, Inc.

F. Hoffmann-La Roche Ltd.

Agilent Technologies, Inc.

These companies are actively engaged in technological advancements, strategic partnerships, and product launches to strengthen their market position.

Key Market Developments

In 2023, Pacific Biosciences launched Revio™, a next-generation SMRT sequencing platform designed to deliver higher throughput and accuracy.

Oxford Nanopore Technologies partnered with a leading hospital network in the U.S. in 2024 to implement real-time sequencing solutions for infectious disease monitoring.

Illumina announced an AI-integrated bioinformatics platform in 2023, enhancing TGS data interpretation and variant analysis.

Scope of Work – Global Third-Generation Sequencing Market

Report Metric Details

Market Size (2023) USD 8.3 billion

Projected Market Size (2031) USD 18.9 billion

CAGR (2023-2031) 10.8%

Market Segments System Type (Nanopore, SMRT, etc.), End-Use (Hospitals, Research, Pharma)

Growth Drivers Personalized medicine demand, Genomics research investments, AI integration

Opportunities Infectious disease applications, Cloud-based bioinformatics solutions

FAQs

1. What is the current market size of the Global Third-Generation Sequencing Market?

The market was valued at USD 8.3 billion in 2023 and is projected to grow significantly during the forecast period.

2. What is the major growth driver of the Global Third-Generation Sequencing Market?

The major growth driver is the increasing adoption of TGS in personalized medicine and genomics research, along with technological advancements in sequencing platforms.

3. Which is the largest region during the forecast period in the Global Third-Generation Sequencing Market?

North America is the largest region, accounting for a significant share due to its advanced research infrastructure, high healthcare expenditure, and presence of key industry players.

4. Which segment accounted for the largest market share in the Global Third-Generation Sequencing Market?

The Nanopore Sequencing segment led the market in 2023 due to its real-time sequencing capability and high portability, making it ideal for clinical and field applications.

5. Who are the key market players in the Global Third-Generation Sequencing Market?

Leading players include Pacific Biosciences, Oxford Nanopore Technologies, Illumina, Thermo Fisher Scientific, QIAGEN, and BGI Genomics, among others.

This comprehensive market research provides deep insights into the Global Third-Generation Sequencing Market, covering growth trends, key drivers, restraints, opportunities, and competitive dynamics.